Literature DB >> 22566567

Dynamic roles of type I and type II IFNs in early infection with Mycobacterium tuberculosis.

Ludovic Desvignes1, Andrea J Wolf, Joel D Ernst.   

Abstract

Although the protective role of type II IFN, or IFN-γ, against Mycobacterium tuberculosis has been established, the effects of type I IFNs are still unclear. One potential confounding factor is the overlap of function between the two signaling pathways. We used mice carrying null mutations in the type I IFNR, type II IFNR, or both and compared their immune responses to those of wild-type mice following aerosol infection with M. tuberculosis. We discovered that, in the absence of a response to IFN-γ, type I IFNs play a nonredundant protective role against tuberculosis. Mice unable to respond to both types of IFNs had more severe lung histopathology for similar bacterial loads and died significantly earlier than did mice with impaired IFN-γ signaling alone. We excluded a role for type I IFN in T cell recruitment, which was IFN-γ dependent, whereas both types of IFNs were required for optimal NK cell recruitment to the lungs. Type I IFN had a time-dependent influence on the composition of lung myeloid cell populations, in particular by limiting the abundance of M. tuberculosis-infected recruited macrophages after the onset of adaptive immunity. We confirmed that response to IFN-γ was essential to control intracellular mycobacterial growth, without any additional effect of type I IFN. Together, our results imply a model in which type I IFN limit the number of target cells that M. tuberculosis can infect in the lungs, whereas IFN-γ enhances their ability to restrict bacterial growth.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22566567      PMCID: PMC3370955          DOI: 10.4049/jimmunol.1200255

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  54 in total

1.  Mycobacterium tuberculosis infects dendritic cells with high frequency and impairs their function in vivo.

Authors:  Andrea J Wolf; Beth Linas; Giraldina J Trevejo-Nuñez; Eleanor Kincaid; Toshiki Tamura; Kiyoshi Takatsu; Joel D Ernst
Journal:  J Immunol       Date:  2007-08-15       Impact factor: 5.422

2.  Virulence of a Mycobacterium tuberculosis clinical isolate in mice is determined by failure to induce Th1 type immunity and is associated with induction of IFN-alpha /beta.

Authors:  C Manca; L Tsenova; A Bergtold; S Freeman; M Tovey; J M Musser; C E Barry; V H Freedman; G Kaplan
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-24       Impact factor: 11.205

3.  Type I IFN contributes to NK cell homeostasis, activation, and antitumor function.

Authors:  Jeremy B Swann; Yoshihiro Hayakawa; Nadeen Zerafa; Kathleen C F Sheehan; Bernadette Scott; Robert D Schreiber; Paul Hertzog; Mark J Smyth
Journal:  J Immunol       Date:  2007-06-15       Impact factor: 5.422

4.  Type I interferons in combination with bacterial stimuli induce apoptosis of monocyte-derived dendritic cells.

Authors:  M Lehner; T Felzmann; K Clodi; W Holter
Journal:  Blood       Date:  2001-08-01       Impact factor: 22.113

5.  Interferon alpha/beta-mediated inhibition and promotion of interferon gamma: STAT1 resolves a paradox.

Authors:  K B Nguyen; L P Cousens; L A Doughty; G C Pien; J E Durbin; C A Biron
Journal:  Nat Immunol       Date:  2000-07       Impact factor: 25.606

Review 6.  STAT activation and differential complex formation dictate selectivity of interferon responses.

Authors:  Joanna Wesoly; Zofia Szweykowska-Kulinska; Hans A R Bluyssen
Journal:  Acta Biochim Pol       Date:  2007-03-09       Impact factor: 2.149

7.  Lymphocyte recruitment and protective efficacy against pulmonary mycobacterial infection are independent of the route of prior Mycobacterium bovis BCG immunization.

Authors:  Umaimainthan Palendira; Andrew G D Bean; Carl G Feng; Warwick J Britton
Journal:  Infect Immun       Date:  2002-03       Impact factor: 3.441

8.  Adjunctive treatment of disseminated Mycobacterium avium complex infection with interferon alpha-2b in a patient with complete interferon-gamma receptor R1 deficiency.

Authors:  Carla M Ward; Harumi Jyonouchi; Sergei V Kotenko; Sergey V Smirnov; Rakesh Patel; Helen Aguila; George McSherry; Barry Dashefsky; Steven M Holland
Journal:  Eur J Pediatr       Date:  2006-11-21       Impact factor: 3.183

9.  The hypervirulent Mycobacterium tuberculosis strain HN878 induces a potent TH1 response followed by rapid down-regulation.

Authors:  Diane Ordway; Marcela Henao-Tamayo; Marisa Harton; Gopinath Palanisamy; Jolynn Troudt; Crystal Shanley; Randall J Basaraba; Ian M Orme
Journal:  J Immunol       Date:  2007-07-01       Impact factor: 5.422

10.  IFN-beta improves BCG immunogenicity by acting on DC maturation.

Authors:  Elena Giacomini; Maria Elena Remoli; Valérie Gafa; Manuela Pardini; Lanfranco Fattorini; Eliana M Coccia
Journal:  J Leukoc Biol       Date:  2008-12-04       Impact factor: 4.962

View more
  80 in total

1.  The impact of ISGylation during Mycobacterium tuberculosis infection in mice.

Authors:  Jacqueline M Kimmey; Jessica A Campbell; Leslie A Weiss; Kristen J Monte; Deborah J Lenschow; Christina L Stallings
Journal:  Microbes Infect       Date:  2017-01-10       Impact factor: 2.700

2.  Interdependence between Interleukin-1 and Tumor Necrosis Factor Regulates TNF-Dependent Control of Mycobacterium tuberculosis Infection.

Authors:  Nelson C Di Paolo; Shahin Shafiani; Tracey Day; Thalia Papayannopoulou; Thalia Papayannoupoulou; David W Russell; Yoichiro Iwakura; David Sherman; Kevin Urdahl; Dmitry M Shayakhmetov
Journal:  Immunity       Date:  2015-12-15       Impact factor: 31.745

3.  Refractory polymyositis undergoing remission following antitubercular therapy.

Authors:  Durga Prasanna Misra; Sukesh Edavalath; Abhra Chandra Chowdhury; Vikas Agarwal
Journal:  BMJ Case Rep       Date:  2015-04-22

4.  STIM1 controls T cell-mediated immune regulation and inflammation in chronic infection.

Authors:  Ludovic Desvignes; Carl Weidinger; Patrick Shaw; Martin Vaeth; Theo Ribierre; Menghan Liu; Tawania Fergus; Lina Kozhaya; Lauren McVoy; Derya Unutmaz; Joel D Ernst; Stefan Feske
Journal:  J Clin Invest       Date:  2015-05-04       Impact factor: 14.808

Review 5.  Extracellular traps and macrophages: new roles for the versatile phagocyte.

Authors:  Devin M Boe; Brenda J Curtis; Michael M Chen; Jill A Ippolito; Elizabeth J Kovacs
Journal:  J Leukoc Biol       Date:  2015-04-15       Impact factor: 4.962

6.  Mycobacterium tuberculosis Inhibits Autocrine Type I IFN Signaling to Increase Intracellular Survival.

Authors:  Dallas A Banks; Sarah E Ahlbrand; V Keith Hughitt; Swati Shah; Katrin D Mayer-Barber; Stefanie N Vogel; Najib M El-Sayed; Volker Briken
Journal:  J Immunol       Date:  2019-03-04       Impact factor: 5.422

7.  Interferon γ and Tumor Necrosis Factor Are Not Essential Parameters of CD4+ T-Cell Responses for Vaccine Control of Tuberculosis.

Authors:  Mark T Orr; Hillarie Plessner Windish; Elyse A Beebe; David Argilla; Po-Wei D Huang; Valerie A Reese; Steven G Reed; Rhea N Coler
Journal:  J Infect Dis       Date:  2015-01-30       Impact factor: 5.226

Review 8.  Type I interferon: the mediator of bacterial infection-induced necroptosis.

Authors:  Qinglin Du; Jianping Xie; Ha-Jeong Kim; Xiaojing Ma
Journal:  Cell Mol Immunol       Date:  2012-10-22       Impact factor: 11.530

9.  Autophagy protects against active tuberculosis by suppressing bacterial burden and inflammation.

Authors:  Eliseo F Castillo; Alexander Dekonenko; John Arko-Mensah; Michael A Mandell; Nicolas Dupont; Shanya Jiang; Monica Delgado-Vargas; Graham S Timmins; Dhruva Bhattacharya; Hongliang Yang; Julie Hutt; C Rick Lyons; Karen M Dobos; Vojo Deretic
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-23       Impact factor: 11.205

10.  Deletion of the cyclic di-AMP phosphodiesterase gene (cnpB) in Mycobacterium tuberculosis leads to reduced virulence in a mouse model of infection.

Authors:  Jun Yang; Yinlan Bai; Yang Zhang; Vincent D Gabrielle; Lei Jin; Guangchun Bai
Journal:  Mol Microbiol       Date:  2014-05-23       Impact factor: 3.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.